InVision Medical Technology
ActiveAI Diagnosis of Heart Disease
About
At InVision, we use AI to help streamline the interpretation of ultrasounds and identify diseases that may have been missed by human readers. Our models have been tightly integrated into the clinical workflow to allow easy usage by clinicians. Our work has previously been peer-reviewed and published in several top medical venues, including Nature (2020), Nature Medicine (2021), Lancet Digital Health (2021), JAMA Cardiology (2022). Results from our blinded and randomized clinical trial on evaluating cardiac function have also been recently presented as a Late Breaking Clinical Trial at the European Society of Cardiology.
Founders · 2
MD 2014, UCSF Internal Medicine Residency 2017, Stanford Cardiology Fellowship 2020, Stanford Cardiologist, Cedars Sinai Medical Center
PhD Computer Science 2022, Stanford University BS Computer Science 2015, California Institute of Technology
Launch
InVision develops AI to streamline the interpretation of heart ultrasounds and identify undiagnosed disease.
InVision develops AI tools to streamline interpretation of heart ultrasounds and identify undiagnosed heart disease. They announce integration into clinical workflow, ongoing blinded randomized trial in cardiology, and plans for FDA clearance and clinical trials for screening various cardiac conditions.
From the original launch (Aug 2022) — may be outdated.
Formerly “EchoNet”, “InVision”
Related startups
A new way of seeing inside the human body.
AI-Powered Clinical Decision Support & Ambient Scribing
